Publication details
Economic Issues and Viability of Gene-Based Molecular Therapies for Cardiovascular Disease
| Authors | |
|---|---|
| Year of publication | 2026 |
| Type | Article in Periodical |
| Magazine / Source | Canadian Journal of Cardiology |
| MU Faculty or unit | |
| Citation | |
| web | https://www.sciencedirect.com/science/article/pii/S0828282X2600245X |
| Doi | https://doi.org/10.1016/j.cjca.2026.03.004 |
| Keywords | gene therapy; cardiovascular disease; health economics; cost effectiveness analysis; payment models; health technology assessment |
| Description | Gene-based molecular therapies (GMTs) have the potential to transform cardiovascular care through single-administration interventions with durable or curative effects. RNA-based therapies, such as inclisiran, are already approved for lipid lowering, but no in vivo gene addition or gene-editing therapy has yet received approval for a primary cardiovascular indication. As these therapies approach clinical readiness, their adoption will be shaped less by scientific feasibility than by economic viability. This commentary examines the key economic barriers to pricing, reimbursement, and adoption of cardiovascular GMTs, and reviews emerging payment models aimed at aligning cost with long-term therapeutic value. |
| Related projects: |